T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 463
Format: PDF
Product Line: Full Report
Product Code: LMFR0028
Release Date: June of 2019
Category: Tag:
Loading...

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019. The report brings you up-to-date information about major pharmaceutical and technology companies active in the field, state of the art and emerging next generation technologies, subject and economic terms of partnering deals and a pipeline analysis of product candidates including clinical experiences.

Analysis is based on the profiles of 56 Big Pharma and technology companies covering company background/history, financial situation, technology overview, partnering activities and pipeline overviw. 38 different technologies to create bispecific T-cell and NK cell engaging antibodies are profiled in depth. Pipeline analysis is based on the profiles of 90 drug candidates in development. Sources of information are 237 scientific references. Non-scientific sources of information, such as press releases, annual reports and presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.

Immunotherapy of cancer with T-cells oder NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.

Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.

This report will show you that there are plenty of opportunities for players in the field, including major pharmas, technology providers and investors.

This report will inform you about Big Pharma’s

  • In-house technologies and product candidates;
  • Technology and target in-licensing preferences;
  • Preferred product profile (half-life, safety features, effector cell type, and target type);
  • Economic deal terms.

38 technology companies with T-cell and NK cell engaging bispecific antibody technologies are analyzed regarding their

  • In house established technologies to redirect T-cells and NK cells or engage cotimulatory molecules;
  • Emerging technologies to generate bispecifics with longer half-life, greater safety, higher efficacy and to target intracellular targets via peptide MHC complexes;
  • In-house product candidates in development (technology used, construct, target, indication, R&D phase).

The profiles of 58 clinical stage and 25 non-clinical development stage T-cell and NK cell engaging bispecific antibodies form the basis of

  • Competitor analysis for a given target
  • Description of popular targets and bispecific antibody technologies
  • Discussion of product candidates from emerging next generation technologies
  • Learnin from clinical experience in hematologic and solid tumor indications.

So far, the attrition rate of T-cell and NK cell engaging antibodies is relatively low (12%). This report identified the terminated bispecific T-cell engager projects and the reasons for discontinuation.

This report also analyzes the financial „maturity“ of technology companies and their specific sources of funding. Overall, raising money for bispecific T-cell and NK cell engagers is no fundamental problem

What will you find in the report?

  • Profiles of 56 companies active in the field;
  • Comprehensive description and analysis of 38 established or emerging T-cell or NK-cell engaging antibody technologies;
  • Profiles of one approved, 89 T-cell or NK-cell engaging bispecific antibodies in all phases of development, and analysis of eight discontinued bispecific T-cell engagers;
  • Technology selection and preferences of major pharma;
  • Key characteristics of technologies with clinical stage drug candidates;
  • Emerging alternative bi- and trispecific formats;
  • Target selection and competition of drug candidates;
  • Competitive evaluation of clinical experience with bispecific T-cell and NK cell engagers;
  • Economic terms of collaboration and licensing deals;
  • Sources of financing.

Who will benefit from the report?

  • Venture capital, private equity and investment managers;
  • Financial analysts;
  • CFO;
  • Business development and licensing (BDL) specialists;
  • Marketing managers;
  • CEO, COO and managing directors;
  • Corporate strategy analysts and managers;
  • Chief Technology Officer;
  • R&D Management in Oncology;
  • R&D Portfolio, Technology and Strategy Management;
  • Cell technology and manufacturing specialists;
  • Clinical and preclinical development specialists.

Table of Contents

1          Executive Summary

2          Introduction

3          Stakeholder and Technology Analysis of Major Pharmaceutical Companies

4          Stakeholder and Technology Analysis of Technology Companies

4.1       Technology Companies with Ig-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies

4.2       Technology Companies with Fc-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies

4.3       Technology Companies with Binder-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies

4.4       Technology Companies with Special T-cell or NK Cell Engaging Bispecific Antibody Technologies

 

5          Pipeline Analysis of T-Cell and NK Cell Engaging Bispecific Antibodies

5.1       Tumor Targeting & Effector Cell Engagement

5.2       Clinical Experience with BCMA-Targeted T-Cell Engaging Bispecific Antibodies

5.3       Clinical Experience with CD33-Targeted T-Cell Engaging Bispecific Antibodies

5.4       Clinical Experience with CD20-Targeted T-cell Redirecting Bispecific Antibodies

5.5       Clinical Experience with CD123-Targeted T-Cell Engaging Bispecific Antibodies

5.6       Clinical Experience with PSMA-Targeted T-Cell Engaging Bispecific Antibodies

5.7       Clinical Experience with Other Solid Tumor Targeted T-Cell Engaging Bispecific Antibodies

5.8       Clinical Experience with Other Blood Cancer Targeted T-Cell Engaging Bispecific Antibodies

5.9       Discontinued Clinical Stage T-Cell Redirecting Bispecific Antibodies

 

6          Sources of Financing and Partnering Deals of Technology Companies

 

  1. Company Profiles

7.1.      Major Pharmaceutical Companies with Bispecific T-Cell or NK Cell Engaging Antibodies

7.2       Technology Companies with Ig-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies

7.3       Technology Companies with Fc-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies

7.4       Technology Companies with Binder-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies

7.5       7.5 Technology Companies with Special Bispecific T-Cell or NK Cell Engaging Antibody Technologies

  • AbbVie
  • Abpro
  • Adimab
  • Affimed Therapeutics
  • Alligator Bioscience
  • Amgen
  • Amphivena Therapeutics
  • Aptevo Therapeutics
  • Arbele
  • Astellas Pharma
  • AstraZeneca
  • BenHealth Biopharmaceuticals
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Crescendo Biologics
  • CytomX Therapeutics
  • Dragonfly Theraputics
  • Eli Lilly
  • GEMoaB Monoclonals
  • Generon
  • Genmab
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • GT Biopharma
  • Harpoon Therapeutics
  • IGM Biosciences
  • Immatics Biotechnologies
  • Immunocore
  • Innate Pharma
  • Inovio Pharmaceuticals
  • Janssen
  • Lava Therapeutics
  • MacroGenics
  • Maverick Therapeutics
  • Merck & Co.
  • Merus
  • Mogam Institute for Biomedical Research (MIBR)
  • Molecular Partners
  • NJCTTQ
  • Novartis
  • Numab
  • Pfizer
  • Pieris Pharmaceuticals
  • PsiOxus Therapeutics
  • Regeneron Pharmaceuticals
  • Revitope Oncology
  • Roche
  • Sanofi
  • Servier
  • Takeda Pharmaceutical Co.
  • TeneoBio
  • VBL Therapeutics
  • Xencor
  • YZY Biopharma
  • Zymeworks

 

8          Technology Profiles

8.1       Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

8.2       Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

8.3       Binder Only-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologie

8.4       Novel „Special“ T-Cell and NK Cell Engaging Bispecific Antibody Technologies

  • ADAPTIR Bispecific, Modular Protein Technology
  • Anticalin Technology
  • ART-Ig Technology
  • Asymmetric head-to-tail 2+1 T-Cell Bispecific (2+1 TCB) IgG antibody platform
  • Azymetric Platform
  • BEAT Technology: Bispecific Engagement by Antibodies based on the T Cell Receptor
  • Biclonics Technology
  • Bispecific IgM Antibodies
  • COBRA Technology
  • CODV-Ig Technology
  • DARPin Multispecifics
  • DNA-Encoded Bi-specific T Cell Engagers (dBiTEs)
  • DuoBody Technolog
  • DVD-Ig Bispecific Antibody Technology
  • GammaDelta T-cell Engager Platform
  • HLE-BiTE Bispecific T Cell Engager Technology
  • Humabody Technology
  • Human Heavy Chain Antibody (UniAb) Platform for Bispecifics
  • ImmunoTherapy Antibody (ITab) technology platform
  • ITE Technology
  • Knobs-into-holes Technology
  • MATCH Technology
  • MultiMab Technology with TetraBi Format
  • NK Cell Engager (NKCE) Technology
  • ROCK Platform: Redirected Optimized Cell Killing
  • RUBY Technology
  • T cell Engaging Antibody Circuits (TEACs)
  • T cell-engaging Bispecific Probody Technology
  • T-Cell Engaging Full Length Bispecific Antibody Platform
  • TCER: Bispecific T-cell Engaging Receptor Molecules
  • TCR-based ImmTAC Technology
  • TriKE and TetraKE Technologies
  • TriNKET Technology
  • TriTAC & ProTriTAC Technologies
  • Tumor-Specific Immuno-Gene Therapy (T-SIGn)
  • Veloci-Bi Technology
  • XmAb Bispecific Fc Technology
  • YBody Bispecific Antibody Technology

 

9          Drug and Drug Candidate Profiles

9.1.1    A-319

9.1.2    A-337

9.1.3    ABBV-428

9.1.4    ABP-100

9.1.5    ABP-110

9.1.6    ABP-150

9.1.7    AFM13

9.1.8    AFM14

9.1.9    AFM26

9.1.10  ALG.APV-527

9.1.11  AMG 160

9.1.12  AMG 212

9.1.13  AMG 330

9.1.14  AMG 420

9.1.15  AMG 424

9.1.16  AMG 427

9.1.17  AMG 562

9.1.18  AMG 596

9.1.19  AMG 673

9.1.20  AMG 701

9.1.21  AMG 757

9.1.22  AMV564

9.1.23  Anti-FLT3

9.1.24  Anti-ROR1

9.1.25  APVO436

9.1.26  ARB-201

9.1.27  Blincyto

9.1.28  BMS-986277

9.1.29  CB307

9.1.30  CC-93269

9.1.31  ERY974

9.1.32  GBR1302

9.1.33  GBR1342

9.1.34  GBR1372

9.1.35  GEM3PSCA

9.1.36  GEM333

9.1.37  GEN3013

9.1.38  HPN217

9.1.39  HPN328

9.1.40  HPN424

9.1.41  HPN536

9.1.42  IGM2323

9.1.43  IMC-C103C

9.1.44  IMC-F106C

9.1.45  IMCgp100

9.1.46  IMCnyeso

9.1.47  IPH61

9.1.48  JNJ-63709178

9.1.49  JNJ-6389808

9.1.50  JNJ-64007957

9.1.51  JNJ-64407564

9.1.52  JNJ-67571244

9.1.53  M701

9.1.54  M802

9.1.55  MCLA-117

9.1.56  MCLA-145

9.1.57  MG1122

9.1.58  MGD006

9.1.59  MGD007

9.1.60  MGD009

9.1.61  MGD014

9.1.62  MO0310

9.1.63  ND021

9.1.64  NG-641

9.1.65  OXS-1615

9.1.66  OXS-3550

9.1.67  OXS-C3550

9.1.68  PF-06671008

9.1.69  PF-06863135

9.1.70  PRS-342

9.1.71  REGN1979

9.1.72  REGN4018

9.1.73  REGN5458

9.1.74  RG6026

9.1.75  RG6160

9.1.76  RG6194

9.1.77  RG7802

9.1.78  RG7827

9.1.79  RG7828

9.1.80  SAR440234

9.1.81  TNB-383B

9.1.82  TNB-486

9.1.83  TNB-585

9.1.84  TSA(1)-CD28 & TSA(2)-CD28

9.1.85  VB-600

9.1.86  XmAb13676

9.1.87  XmAb14045

9.1.88  XmAb18087

9.1.89  XmAb23104

9.1.90  Y111

 

10        References

Tables

Tables in the Text

 

Table 1           Big Pharma’s In-House and In-Licensed T-Cell and NK-Cell Engaging Bispecific Antibody Technologies

Table 2           Big Pharma’s Preferences for T-Cell and NK-Cell Engaging Bispecific Antibody Technologies

Table 3           Big Pharma’s Preferences for Half-Life Extension in T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 4           Big Pharma’s Preferred Targets for T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 5           Economic Terms of Big Pharma’s Collaboration & Licensing Agreements for T-Cell & NK Cell Engaging Bispecific Antibody Technologies

Table 6           Main Characteristics of Big Pharma’s T-cell Engaging Bispecific Antibody Technologies

Table 7           Safety and Effector Cell Features of Big Pharma’s T-cell Engaging Bispecific Antibody Technologies

Table 8           Overview of Applied Technology, Target and Highest R&D Phase of Big Pharma’s Proprietary T-cell and NK Cell Engaging Bispecific Antibodies

Table 9           Overview of Technology Companies with T-Cell and NK-Cell Engaging Bispecific Antibody Technologies

Table 10         Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Ig-Based T-Cell or NK Cell Engaging Bispecific Technologies

Table 11         Overview of Targets and Highest R&D Phase of Ig-based T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 12         Overview of Partnering Deals of Technology Companies with Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 13         Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Fc-Based T-Cell or NK Cell Engaging Bispecific Technologies

Table 14         Overview of Targets and Highest R&D Phase of Fc-based T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 15         Overview of Partnering Deals of Technology Companies with Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 16         Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Binder-Based T-Cell or NK Cell Engaging Bispecific Technologies

Table 17         Overview of Targets and Highest R&D Phase of Binder-based T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 18         Overview of Partnering Deals of Technology Companies with Binder-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 19         Overview of Special Technology Companies for Safety Features and Mode of Cell Engagement of T-Cell or NK Cell Engaging Bispecific Technologies

Table 20         Overview of Targets and Highest R&D Phase of Various T-Cell and NK Cell Engaging Antibodies from Technology Companies

Table 21         Overview of Partnering Deals of Technology Companies with Various T-Cell and NK Cell Engaging Bispecific Antibody Technologies

Table 22         Overview of Drug Profiles for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase

Table 23         Overview of Not Profiled Drug Candidates for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase

Table 24         Tumor Target, Effector Cell Engagement, Tumor Type and Number of Bispecific Antibodies per Phase of T-Cell and NK Cell Engaging Bispecific Antibodies

Table 25         Pipeline of BCMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 26         Pipeline of CD33-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 27         Pipeline of CD20-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 28         Pipeline of CD123-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 29         Pipeline of PSMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies

Table 30         Financing Sources of Technology Companies with Bispecific T-Cell and NK Cell Engaging Antibody Technologies

Table 31         Amgen’s Bispecific T-Cell Engager Pipeline

Table 32         Celgene’s Clinical Pipeline of Bispecific T-Cell Redirecting Antibodies

Table 33         Janssen’s Clinical Pipeline of T-Cell Redirecting Bispecific Antibodies

Table 34         Pfizer’s T-cell Engaging Bispecific Antibody Pipeline

Table 35         Roche’s Pipeline of Clinical Stage T-Cell Redirecting Bispecific Antibodies

Table 36         Sanofi’s Bispecific T-Cell and NK Cell Engager Pipeline

Table 37         Abpro’s Pipeline of T-Cell Engaging TetraBi Antibodies

Table 38         Merus‘ Biclonics Development Pipeline

Table 39         Regeneron Pharmaceuticals T-Cell Engaging Bispecific Antibody Pipeline

Table 40         TeneoBio’s Pipeline of T-Cell Engaging Bi- and Multi-Specific Human Heavy Chain Antibodies

Table 41         YZY Biopharma‘s Pipeline of T-Cell Redirecting Bispecific Antibodies

Table 42         Partnering Terms for Zymeworks‘ Azymetric Technology

Table 43         Pipeline of ADAPTIR Molecules from Aptevo Therapeutics

Table 44         MacroGenics‘ Clinical Stage Pipeline of T-Cell Redirecting Bispecific DART Antibodies

Table 45         Xencor’s Bispecific T-Cell Engaging Antibody Pipeline

Table 46         Generon’s Pipeline of Bispecific ITab Antibodies

Table 47         Harpoon Therapeutics‘ TriTAC Pipeline

Table 48         Affimed Therapeutics‘ T-Cell and NK-Cell Engaging Antibody Pipeline

Table 49         GT Biopharma‘ Pipeline of Tri- and Tetra-Specific NK Cell Engagers

Table 50         Goals and Terms of Immunocore’s Industry Partnering Deals for ImmTAC Technology

Table 51         Immuncore’s Wholly Owned and Partnered Development Pipeline of ImmTACs

Table 52         Blincyto Global Sales

Table 53         Clinical Studies with IMCgp100

AbbVie

Abpro

Adimab

Affimed Therapeutics

Alligator Bioscience

Amgen

Amphivena Therapeutics

Aptevo Therapeutics

Arbele

Astellas Pharma

AstraZeneca

BenHealth Biopharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Crescendo Biologics

CytomX Therapeutics

Dragonfly Theraputics

Eli Lilly

GEMoaB Monoclonals

Generon

Genmab

GlaxoSmithKline

Glenmark Pharmaceuticals

GT Biopharma

Harpoon Therapeutics

IGM Biosciences

Immatics Biotechnologies

Immunocore

Innate Pharma

Inovio Pharmaceuticals

Janssen

Lava Therapeutics

MacroGenics

Maverick Therapeutics

Merck & Co.

Merus

Mogam Institute for Biomedical Research (MIBR)

Molecular Partners

NJCTTQ

Novartis

Numab

Pfizer

Pieris Pharmaceuticals

PsiOxus Therapeutics

Regeneron Pharmaceuticals

Revitope Oncology

Roche

Sanofi

Servier

Takeda Pharmaceutical Co.

TeneoBio

VBL Therapeutics

Xencor

YZY Biopharma

Zymeworks